Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stratification marker study for immune checkpoint inhibitors in advanced or recurrent NSCLC
jRCT1031210706Recruiting
- Sponsor
- Kanagawa Prefectural Cancer Center
- Start
- Mar 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of pembrolizumab, nivolumab, atezolizumab, durvalumab, avelumab and 2 more in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Kanagawa Prefectural Cancer Center. Primary endpoint: Primary overall survival comparison in cohort A. Started Mar 2022; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1031210706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031210706.